Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthos Therapeutics Inc.

www.anthostherapeutics.com

Latest From Anthos Therapeutics Inc.

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

Ferring And Blackstone Launch Gene Therapy Company

The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.

Gene Therapy Strategy

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Deals Financing

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Anthos Therapeutics Inc.
  • Senior Management
  • John Glasspool, CEO
    Jonathan Freeman, PhD, COO
    Debra Freedholm, Head, Clinical Operations
  • Contact Info
  • Anthos Therapeutics Inc.
    101 Main St.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register